Literature DB >> 21818512

Assessor-blinded study of the metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared with age-matched population of children with warts.

Eva M Volf1, Danielle E Levine, Melissa A Michelon, Shiu-Chung Au, Eshan Patvardhan, Nicole Dumont, Daniel S Loo, Jeffrey Kuvin, Alice B Gottlieb.   

Abstract

Adult patients with psoriasis have an increased prevalence of the metabolic syndrome (MetS) and cardiovascular disease (CVD) risk factors due to elevations of Tumor Necrosis Factor and other inflammatory cytokines.1,2 Recently, higher rates of hyperlipidemia, obesity, hypertension, and diabetes mellitus were seen in patients with juvenile psoriasis.3 Here, we report the interim results of an ongoing study of MetS and CVD risk factors in pediatric psoriasis patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21818512

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  2 in total

Review 1.  Psoriasis comorbidities: complications and benefits of immunobiological treatment.

Authors:  André Vicente Esteves de Carvalho; Ricardo Romiti; Cacilda da Silva Souza; Renato Soriani Paschoal; Laura de Mattos Milman; Luana Pizarro Meneghello
Journal:  An Bras Dermatol       Date:  2016 Nov-Dec       Impact factor: 1.896

2.  Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study.

Authors:  D Thaçi; K Papp; D Marcoux; L Weibel; A Pinter; P-D Ghislain; I Landells; P H Hoeger; K Unnebrink; M M B Seyger; D A Williams; S Rubant; S Philipp
Journal:  Br J Dermatol       Date:  2019-07-25       Impact factor: 9.302

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.